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doi:10.101Prospective Assessment of Health-Related Quality
of Life in Pediatric Patients with Beta-Thalassemia
following Hematopoietic Stem Cell Transplantation
Giovanni Caocci,1 Fabio Efficace,2 Francesca Ciotti,3 Maria Grazia Roncarolo,3
Adriana Vacca,1 Eugenia Piras,1 Roberto Littera,1 Raji Suleiman Dawood Markous,4
Gary Stephen Collins,5 Fabio Ciceri,3 Franco Mandelli,2 Sarah Marktel,3 Giorgio La Nasa1,6Although hematopoietic stem cell transplantation (HSCT) has been widely used to treat pediatric patients
with beta-thalassemia major, evidence showing whether this treatment improves health-related quality of
life (HRQoL) is lacking. We used child-self and parent-proxy reports to prospectively evaluate HRQoL in
28 children with beta-thalassemia from Middle Eastern countries who underwent allogeneic HSCT in Italy.
The PedsQL 4.0 Generic Core Scales were administered to patients and their parents 1 month before
and 3, 6, and 18 months after transplantation. Two-year overall survival, thalassemia-free survival, mortality,
and rejection were 89.3%, 78.6%, 10.9% and 14.3%, respectively. The cumulative incidence of acute and
chronic graft-versus-host disease (GVHD) was 36% and 18%, respectively. Physical functioning declined
significantly from baseline to 3 months after HSCT (median PedsQL score, 81.3 vs 62.5; P 5 .02), but
then increased significantly up to 18 months after HSCT (median score, 93.7; P5 .04). Agreement between
child-self and parent-proxy ratings was high. Chronic GVHD was the most significant factor associated with
lowerHRQoL scores over time (P5.02). The child-self and parent-proxy reports showed improved HRQoL
in the children with beta-thalassemia after HSCT. Overall, our study provides preliminary evidence-based
data to further support clinical decision making in this area.
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The many advances in the treatment of patients
with beta-thalassemia major have dramatically inproved
survival rates over the past decade [1,2]. Nevertheless,
several problems continue to hamper the management
of this chronic disease, including poor compliance
with iron chelation therapy, endocrine problems, the
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[3]. Children suffering from this serious life-limiting
and potentially life-threatening condition report a sub-
stantial reduction of social relationships and an overall
sense of isolation [4]. Allogeneic hematopoietic stem
cell transplantation (HSCT) from an HLA-matched
donor remains the only potential cure [5]. Unfortu-
nately, this procedure is burdened by a variable inci-
dence (6%-30%) of transplantation-related mortality
(TRM), depending on the pretransplantation risk strat-
ification according to Lucarelli et al. [6]. Acute and
chronic graft-versus-host disease (GVHD) are frequent
complications and contribute significantly to the risk of
TRM [7,8]. Moreover, the posttransplantation phase is
associated with increased clinical and laboratory tests,
frequent hospital admissions for infections, adverse
drug effects, and GVHD-related complications, all of
which contribute to significant impairment of health-
related quality of life (HRQoL).
HRQoL is generally conceptualized as a multidi-
mensional construct referring to patients’ perceptions
of the impact of disease and treatment on their physi-
cal, psychological, and social functioning and well
being [9-11]. Despite the worldwide diffusion of861
862 Biol Blood Marrow Transplant 17:861-866, 2011G. Caocci et al.thalassemia and its high incidence in developing
countries (the Mediterranean area, Middle East, and
Asia), HRQoL has been investigated only rarely
[12-16]. In fact, the literature contains only two
studies on the HRQoL of thalassemia patients after
HSCT [17,18]. In the first of these studies, good
HRQoL outcomes were obtained in a cohort of 19
adult thalassaemia patients who received a transplant
from anHLA-matched unrelated donor [17]. More re-
cently, Cheuk et al. [18] investigated HRQoL in 21
thalassemia patients who underwent allogeneic
HSCT from HLA-matched sibling donors and found
that HRQoL scores in the post-HSCT period were
similar to those reported for conventionally treated
patients. Both of these previous studies were cross-
sectional and provided only limited evidence, however.
To the best of our knowledge, the present study is
the first to prospectively evaluate HRQoL in thalasse-
mia patients before and up to 18 months after HSCT.
Toward this aim, we investigated 28 thalassemic chil-
dren from Middle Eastern countries who underwent
allogeneic HSCT from an HLA-matched donor in
the bone marrow transplant centers of the IRCCS San
Raffaele Hospital in Milan and the R. Binaghi Hospital
in Cagliari. We also examined the level of agreement
between child-self and parent-proxy ratings ofHRQoL.
Previous studies in childhood cancer have shown that
parental ratings of their child’s HRQoL tend to be
lower and possibly reflect a series of parental distress
factors [19,20]. In a recent review of HRQoL, the
authors strongly advocate the need for prospective
research into HRQoL after pediatric HSCT, with
particular emphasis on the contribution of family
factors [21].METHODS
Patients and Clinical Procedures
Between November 2006 and August 2009, 28
children with thalassemia (17 males and 11 females;
median age, 10 years; range, 5-17 years) underwent al-
logeneicHSCT from anHLA-matched donor. Patient
clinical and sociodemographic characteristics are sum-
marized in Table 1. All patients came to Italy from
Middle Eastern countries to receive HSCT as part of
a larger humanitarian project involving a knowledge-
exchange program with the local doctors. Twenty-
four patients (85.7%) were assigned to risk class 3,
and the remaining 4 were assigned to risk class 2,
according to the criteria proposed by Lucarelli et al.
[6].Written informed consent forHSCTwas provided
by the patients’ parents according to the declaration of
Helsinki. All patients were prepared for HSCT with
a myeloablative conditioning regimen. Supportive
therapy, as well as prophylaxis and treatment of infec-
tions, was homogeneous among participating centers.All patients received cyclosporine and short-term
methotrexate for GVHD prophylaxis. Acute and
chronic GVHD were graded according to the Seattle
criteria [22,23]. After transplantation, the patients
were followed up in Italy for at least 6 months, after
which they returned to their home country for
follow-up care. The mean duration of clinical follow-
up was 24 months.
HRQoL Evaluation
HRQoL was assessed using the PedsQL 4.0
Generic Core Scales. This 23-item multidimentional
questionnaire was designed to evaluate the essential
core domains for pediatric HRQoL, including physi-
cal, emotional, and social functioning as defined by
the World Health Organization, as well as school
functioning [24,25]. The PedQL psychosocial health
summary score represents the sum of items over the
number of items answered in the emotional, social,
and school functioning scales [26]. To create the total
PedsQL score, the mean is computed as the sum of all
items over the number of items answered on all scales.
The reliability, internal consistency, and validity of the
PedsQL questionnaire have been assessed in pediatric
patients with various acute and chronic disorders, as
well as in physically healthy pediatric populations
[24,25]. Each item is rated on a 5-point Likert scale.
The scores for each dimension are calculated as
follows. The mean score is represented by the sum of
the items over the number of items answered, with
missing values replaced by the mean score of the
remaining items. If more than 50% of the items in
a given scale are missing, then the scale score is
not computed. Raw scores are transformed into
standardized scores on a scale of 0-100, with higher
scores representing higher levels of functioning.
The PedsQL 4.0 Generic Core Scales were admin-
istered at baseline (before transplantation) and at 3
months and 6 months after HSCT while in Italy, and
then at 18 months in the patients’ home countries.
The questionnaires were completed in Arabic.
Statistical Analysis
The survival probability of our cohortwas estimated
by the Kaplan-Meier method. Differences between
baseline ratings and measurements performed at 3, 6,
and 18 months post-HSCT were evaluated using the
Mann-Whitney U test. Logistic regression was used to
assess the association between clinical and baseline
HRQoL risk factors and acuteGVHD(aGVHD)onset.
Risk factors considered were age (continuous), iron
chelation (regular or irregular), transfusion frequency
(regular or irregular), serum ferritin level .1300 mg/
dL (yes or no), physical functioning, emotional func-
tioning, social functioning, school functioning, and total
score. Odds ratios (ORs) are reported with 95%
Table 1. Clinical and Sociodemographic Characteristics of 28
Children Who Underwent HSCT for Beta-Thalassemia
Characteristic
Males/females, n 17/11
Age, years, median (range) 10 (5-17)
Language, n (%)
Arabic 22 (79)
Sorani 6 (21)
Religion, n (%)
Muslim 28 (100)
Country, n (%)
Lebanon 8 (28.5)
Kurdistan (Iraq) 9 (32)
Palestine 1 (4)
Syria 10 (35.5)
Months from birth to diagnosis,
median (range)
17 (1-48)
Months from birth to transfusion,
median (range)
19 (2-60)
Months from birth to iron chelation
therapy, median (range)
45 (12-96)
Transfusion regimen, n (%)
Regular (pretransfusion hemoglobin
$9 g/dL)
9 (32)
Slightly irregular (pretransfusion
hemoglobin $7.5 and <9 g/dL)
13 (46.5)
Irregular (pretransfusion hemoglobin
<7.5 g/dL or frequent transfusion
reactions)
6 (21.5)
Iron chelation regimen, n (%)
Regular administration (once daily) 5 (18)
Slightly irregular administration
(at least once a week)
6 (21)
Irregular administration (less than
once a week or none)
17 (61)
Hepatomegaly, n (%) 18 (64)
Hepatitis B or C infection, n (%) 12 (43)
Ferritin >1300 mg/dL, n (%) 22 (79)
Pesaro risk class, n (%)
Class 2 4 (14.3)
Class 3 24 (85.7)
HSCT, n (%)
Haploidentical donor 1 (3.5)
Sibling donor 25 (89.5)
Voluntary donor 2 (7)
Conditioning regimen, n (%)
Treosulfan/thiotepa/fludarabine 6 (21)
Busulfan/cyclosporine 20 (71.5)
Busulfan/thiotepa/cyclosporine 2 (7)
aGVHD incidence, n (%) 10 (36)
aGVHD grade, n (%)
I-II 6 (21.5)
III-IV 4 (14)
cGVHD incidence, n (%) 5 (18)
cGVHD extent, n (%)
Limited 3 (11)
Extensive 2 (7)
Post-HSCT complications, n (%)
Infection 19 (68)
Skin 6 (7)
Neurologic 2 (4)
Renal 4 (21)
Cardiac 1 (4)
Hepatic 1 (4)
Lung 2 (7)
Cystitis 1 (4)
Gut 3 (11)
HSCToutcome, n (%)
Rejection 4 (14)
Mortality 3 (11)
Overall survival 25 (89)
Thalassemia-free survival 22 (79)
Follow-up, months, median (range) 24 (3-34)
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variance was used to investigate the impact of chronic
GVHD (cGVHD) on the physical functioning scale
and total PedsQL score. Primary analysis included the
physical functioning scale; the remaining PedsQL scales
(emotional and social functioning, total PedsQL score,
and psychosocial health) were analyzed on an explor-
atory basis.RESULTS
Clinical Outcomes
In our cohort, the Kaplan-Meier 2-year overall
survival rate was 89.3%, the thalassemia-free survival
rate was 78.6%, the cumulative incidence of TRM
was 10.9%, and the rejection rate was 14.3%. Three
patients died of a transplantation-related cause. The
cumulative incidence of grade I-II and grade III-IV
aGVHD was 21.5% and 14%, respectively. Five of
the 25 transfusion-independent surviving patients
(18%) developed cGVHD. More detailed information
on outcomes is given in Table 1.HRQoL over Time
A total of 28 children were followed up for a period
of 18 months after HSCT. The response rate for QoL
evaluation was 100% at baseline, 71% at 3 months
post-HSCT, 64% at 6 months post-HSCT, and
68% at 18 months post-HSCT.
A primary analysis of physical functioning over time
showed a decline frombaseline to 3months post-HSCT
(median score, 81.3 vs 62.5;P5 .02), followedby a sharp
increase at 6 and 18 months post-HSCT, with median
scores of 76.5 and 93.7, respectively. The improvement
in physical functioning measured at 18 months was sta-
tistically significant compared with baseline (P 5 .04).
Inspection of parent-proxy ratings revealed the same
trend (Figure 1 and Table 2). Higher total PedsQL
scores were observed at 18 months in children aged
\10 years compared with older children, but the differ-
ence was not statistically significant.
The global ratings for well being (total PedsQL)
over time were generally stable from baseline up to 3
months post-HSCT, with median scores of 81 (range,
69.4-89.7) and 75.7 (range, 69.1-82.2), respectively.
These scores then rose to 80.6 (range, 66-85.6) at 6
months post-HSCT and to 94.4 (range, 79.6-96) at
18 months post-HSCT. The difference between
scores at baseline and at 18 months post-HSCT was
statistically significant (P5 .02). No significant differ-
ences over time were seen for the social and emotional
functioning scales or the psychosocial health summary
score (Table 2).
A comparison of the level of agreement between
child-self and parent-proxy ratings revealed that parents
Figure 1. Physical health over time assessed by child-self and parent-proxy reports.
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time points and in all subscales, with the sole exception
of social functioning at 6months post-HSCT.The data
reported in Table 3 suggest that this underestimation of
functioning levels improved over time.
GVHD and HRQoL
Univariate analysis was performed to explore
possible baseline factors associated with the onset of
aGVHD, including clinical risk factors and child- and
parent-reported QoL, but no factor had a statistically
significant relevance (data not shown). Repeated-
measures analysis of variance comparing physical func-
tioning over time between children who developed
cGVHD and those who did not yielded only a marginal
difference (P 5 .057). Nevertheless, a significant time
effect was seen (P\ .01), suggesting similar changes in
physical functioning scores over time in the two groups
of children (P5 .18). There was a significant difference
between the twogroups for the total PedsQLscore,with
higher scores over time in the childrenwithout cGVHD
(P 5 .02). A significant time effect (P\ .01) suggested
that total PedsQL scores changed differently across
treatment and follow-up in these two groups (P5 .017).DISCUSSION
Patients with beta-thalassemia who receive con-
ventional transfusion and iron chelation therapy com-
plain of some of the major clinical and psychological
aspects affecting HRQoL, including the impact of dis-
ease on family stability and dynamics, the difficulty of
living with a chronic illness, frequent hospital visits
for transfusions, and problems complying with iron
chelation therapy administered as nightly s.c. infusions[12,27]. The recent introduction of oral iron-chelating
drugs has improved patient compliance with treatment
somewhat, but unfortunately these drugs remain un-
available in developing countries due to their high
cost. Chronic disorders tend to prolong patients’ de-
pendence on family care, which significantly hampers
autonomy and self-determination. Patients often need
to miss work or school because of frequent medical
checkups, treatments, and hospitalizations. These
problems are particularly crucial in developing coun-
tries, where facilities for the control of these conditions
are extremely limited. In fact, the life expectancy in de-
veloping countries is considerably lower than that of
thalassemia patients born in Western countries [28].
The aim of the present study was to establish whether
HSCT can actually inprove the HRQoL in children
living in disadvantaged countries.
HSCT remains the sole curative treatment for beta-
thalassemia. The outcome ofHSCTdepends in part on
the patient’s pretransplantation clinical condition, in
particular the presence of hepatomegaly, the extent of
liver fibrosis, and the magnitude of iron accumulation
[6]. Thus, thalassemia patients and their families are
faced with the difficult decision of whether to continue
traditional therapy or accept the risks associated with
the potentially curative option of HSCT. Prospective
studies investigating the HRQoL of patients before
and after HSCT might help solve this dilemma.
Only two previous reports have studied HRQoL in
thalassemia patients undergoing unrelated and sibling-
matched HSCT [17,18]. Both of these studies found
good HRQoL after HSCT, but the study designs were
cross-sectional, and data were collected 300 days and
6.5 years after transplantation, respectively.
Our prospective study of 28 children with beta-
thalassemia suggests significant improvements in
Table 2. Individual Median Scores (Range) of QoL Profiles Over Time Assessed by Child-Self and Parent-Proxy Reports
Baseline 3 Months 6 Months 18 Months
Total PedsQL
Child report 80.95 (69.40-89.75) 75.70 (69.08-82.25) 80.60 (66.00-85.67) 94.40 (79.60-96.00)
Parent-proxy report 72.25 (60.35-80.95) 72.80 (63.55-76.40) 74.95 (56.25-86.07) 91.30 (76.50-95.30)
Physical Functioning
Child report 81.30 (56.30-93.80) 62.50 (56.30-74.25) 76.50 (66.40-86.72) 93.70 (82.50-98.50)
Parent-proxy report 79.05 (55.50-87.50) 59.40 (48.45-65.60) 76.50 (56.72-84.40) 91.00 (78.75-95.40)
Social Functioning
Child report 90.00 (78.75-96.25) 88.75 (78.75-100) 87.50 (55.00-90.00) 100 (80.00-100)
Parent-proxy report 82.50 (68.75-92.50) 86.25 (73.75-96.25) 80.00 (71.25-98.75) 100 (80.00-100)
Emotional Functioning
Child report 87.50 (73.75-90.00) 82.50 (75.00-95.00) 80.00 (71.25-87.50) 90.00 (82.50-95.00)
Parent-proxy report 70.00 (50.00-81.25) 80.00 (63.75-90.00) 70.00 (45.00-78.75) 85.00 (75.00-95.00)
Psychosocial Score
Child report 83.30 (72.90-90.42) 82.50 (75.00-90.00) 82.75 (57.62-89.38) 93.30 (82.50-96.70)
Parent-proxy report 68.55 (60.00-80.42) 80.00 (74.38-88.12) 77.50 (58.12-89.38) 91.70 (78.00-95.80)
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of highlighting the changes in the children’s physical
condition over time. The significant decline from
pretransplantation levels observed at 3 months post-
transplantation (P5 .02) was followed by a significant
improvement at 6 and 18 months post-HSCT
(P 5 .04). The median total PedsQL score ranged
from 81 at baseline to 94 at 18 months post-HSCT,
suggesting significantly improved physical health.
This trend was supported by the parent-proxy reports,
which were in close agreement with child-reported
outcomes (Figure 1). These findings are consistent
with recent studies of pediatric HRQoL after HSCT
for other diseases. A longitudinal measurement study
of 99 pediatric patients who underwent autologous
or allogeneic HSCT for leukemia, neuroblastoma,
and other solid tumors showed improved physical
and psychosocial HRQoL after HSCT, as reported
by mothers in standardized questionnaires adminis-
tered before HSCT and at 1-2 years post-HSCT
[21]. In addition, a systematic review of 988 children
who underwent HSCT for leukemia, myelodysplastic
syndrome, lymphoma, or a solid tumor found that
HRQoL was already compromised before HSCT,
was further impaired immediately after conditioning,
but then improved considerably by 4-12 months
post-HSCT [29].
The poor HRQoL that we observed in the early
post-HSCTphase can be attributed to the toxicity bur-
den of chemotherapy reported by patients during andTable 3. Mean Differences between Patient and Parent Scores on
Baseline 3 M
Physical functioning 4.2 (20) 8.3
Emotional functioning 13.4 (19.2) 6.5
Social functioning 6.6 (25.4) 0.5
School functioning 1.2 (21.5)
Total PedsQL score 6.5 (15.6) 5.6
NA indicates not assessed.
Positive signs imply underestimation by the parents, whereas negative signs
because the children did not attend regular lessons during the study period.immediately after HSCT, as well as the number of
stressful events (eg, isolation in a protected environ-
ment for 1-2months, social isolation following hospital
dismissal, increased dependency on parents, difficulty
resuming age-appropriate activities). Indeed, at the
3-month post-HSCT assessment, our results for
overall child well-being (as measured by the total
PedsQL scale), did not show significant differences.
However, at 6 months post-HSCT, we found a steady
improvement on this scale, which reached statistical
significance at 18 months post-HSCT (P 5 .02)
(Table 2). We also noted improved psychosocial,
social, and emotional functioning (Table 2).
The secondary aim of the present study was to
compare parents’ and children’s perspectives of
HRQoL before and after transplantation. Figure 1
and Table 2 show considerable overlap between child
and parent perceptions of HRQoL. However, com-
paring the level of agreement between child-self and
parent-proxy ratings revealed a slight tendency of the
parents to underestimate their child’s HRQoL on all
subscales at all time points. Interestingly, this parental
underestimation of child functioning improved over
time (Table 3). The initial differences in perception
most likely can be attributed to worries or distress fac-
tors surrounding the early post-HSCT period, when
the child’s clinical condition is generally worse [19,20].
Chronic GVHD had a major impact on both phys-
ical functioning and overall well being. The children
who developed cGVHD did not recover to the samethe PedsQL 4.0 at Different Time Points
onths 6 Months 18 Months
(16.5) 4.0 (8.4) 1.3 (8.8)
(22.9) 8.9 (10.9) 3.2 (13.3)
(18.9) 20.6 (21.5) 2.2 (7.3)
NA NA NA
(11.9) 4.5 (7.4) 2.0 (6.3)
imply overestimation. School functioning over time was not assessed,
866 Biol Blood Marrow Transplant 17:861-866, 2011G. Caocci et al.extent as those who did not develop cGVHD, even at
18 months post-HSCT. This finding underscores the
importance of taking every available step to reduce
this serious complication. No significant correlations
were found among clinical baseline risk factors,
HRQoL scores at baseline, and development of
aGVHD.Our cohort was relatively small and included
only childrenwho received a transplant from amatched
sibling donor, however. Our research team is currently
collecting data on the HRQoL of thalassemia patients
receiving transplants from unrelated donors. Although
larger studies are warranted, our findings suggest im-
proved HRQoL in thalassemia patients after HSCT
and definitely add to the scanty literature on this topic.
The important evidence-based data emerging from the
PedsQL questionnaire should help clinicians and
patients alike to make more informed treatment deci-
sions. Child-self and parent-proxy reports represent
a valid methodological approach and make it possible
to obtain unique information on the HRQoL of pedi-
atric patients. Overall, our study provides further
insight into the difficult clinical decision making pro-
cess that surrounds the choice of HSCT for chronic
nonmalignant diseases [30-32].ACKNOWLEDGMENTS
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